ATLASArrowhead Pharmaceuticals (ARWR) earnings date: Nov 24, 2026
Arrowhead Pharmaceuticals (ARWR) reports earnings for the quarter ended Sep 30, 2026 on Tue, Nov 24, 2026, after the close. Analysts expect EPS of -$1.59.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on ARWR
| Last price | $59.90 (-1.0%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.8% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Arrowhead Pharmaceuticals stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Arrowhead Pharmaceuticals reports on Nov 24, 2026. One email the day before, with ATLAS’s read on Arrowhead Pharmaceuticals. You can switch it off at any time.
Alert me before ARWR reportsFree to start. Creating an account takes under a minute.
ARWR earnings at a glance
| Next report (confirmed) | Tue, Nov 24, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$1.59 |
| Last report | Aug 4, 2026 · Miss |
| Beat rate (last 4 reports) | 3 of 4 (75%) |
| Average EPS surprise | +6.2% |
| Average move around a report | ±3.3% (last 4) |
| Sector | Healthcare · Biotechnology |
Arrowhead Pharmaceuticals earnings history: last 4 reports
Arrowhead Pharmaceuticals last reported on Aug 4, 2026: EPS of -$1.36 against an estimate of -$1.23 (-10.6% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 4, 2026 | -$1.23 | -$1.36 | -10.6% | Miss | +1.1% |
| Jun 4, 2026 | $1.45 | $1.64 | +13.1% | Beat | +0.7% |
| May 20, 2026 | $2.91 | $3.09 | +6.2% | Beat | +3.2% |
| May 7, 2026 | -$1.11 | -$0.93 | +16.2% | Beat | -8.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for ARWR
See the fair value, the probability range and the earnings history of Arrowhead Pharmaceuticals on its ATLAS page.
Arrowhead Pharmaceuticals (ARWR) stock analysisPlans from €3.99 a month.
Arrowhead Pharmaceuticals earnings: frequently asked questions
When does Arrowhead Pharmaceuticals (ARWR) report earnings?
Arrowhead Pharmaceuticals is scheduled to report on Tuesday, November 24, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for ARWR?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$1.59 per share (USD). Estimates can change before the report.
How often does ARWR beat earnings estimates?
Of its last 4 reports with a recorded result, Arrowhead Pharmaceuticals beat the EPS estimate 3 times; the average surprise was +6.2%. Past results do not predict the next one.
How much does ARWR move around earnings?
Over its last 4 reports the stock moved an average of 3.3% (absolute, from the close before the report day to the close after it), and finished higher 3 of 4 times.
Did Arrowhead Pharmaceuticals beat earnings estimates last quarter?
Arrowhead Pharmaceuticals last reported on Aug 4, 2026: EPS of -$1.36 against an estimate of -$1.23 (-10.6% surprise), a miss.
How much does ARWR usually move in a day?
On a normal trading day the ATLAS model puts ARWR’s one-day range at about ±2.8%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Tue, Nov 24, 2026
Educational information, not investment advice. Disclaimer